Impact Of Measurable Residual Disease (Mrd) By Multiparameter Flow Cytometry (Mfc): A Real-World Study In 1,076 Patients With Acute Myeloid Leukemia (Aml)

Background: Evaluation of MRD is standard in patients with AML. However, the role of decentralized MRD assessment for risk stratification in AML remains largely unknown, and so it does which methodological aspects are critical to empower the evaluation of MRD with prognostic significance, particularly if using MFC.